Videos

Future treatment for patients with the KRAS G12C mutation in NSCLC shows potential promise, according to a principal investigator studying the AMG 510 inhibitor.

The use of immunotherapy in tandem with chemotherapy is the future of treating patients with NSCLC, according to expert Catherine Shu, MD.

With the emphasis on testing for biomarkers to determine treatment for patients with lung cancer, it's important to make sure the testing will have an impact on clinical decisions.

While physicians are looking to further subclassify TNBC to narrow treatment options, not all of these classifications are actionable in the clinic.

Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that isn't the reality of what id can do for patients. And oncology nurses can help guide patients to the right supportive care for them.

Oncology nurses are the first line of defense when it comes to a patient's psychosocial needs, but they don't often have the time to directly attend to them. Which is where support groups can come in to help.

Elderly patients with AML have long faced limited options for their treatment, but that is no longer the case. However, challenges still remain in the treatment of this patient population.

To extend the quality of life for patients with osteosarcoma, researchers are looking for ways to identify before chemo whether or not they need that treatment.

Genetic testing in cancer care is a relatively new element of the field, but some experts are looking to it to help prevent and understand prostate cancer in racially diverse populations.

New research and techniques indicate an easier path forward for identifying hairy cell leukemia.

MRD can prove useful in the treatment of patients with hairy cell leukemia who relapsed.

For patients with hairy cell leukemia, it's complications after treatment that can be life-threatening.

At the 2019 Hairy Cell Leukemia Foundation Annual Conference new findings showed promise in the safety of vemurafenib to treat patients with hairy cell leukemia.

Chemotherapy is often associated with devastating toxicities, but moxetumomab pasudotox appears to be manageable based on the findings from a new trial.

One expert details why axillary lymph node dissection is vital in the treatment of patients with breast cancer.

Patients with the highest risk of developing a BRCA mutation are not being tested earlier enough and developing these mutations when it's too late. Clinicians can change that.

The future of treating patients with triple-negative breast cancer is bright, but more needs to be done to address mutations early on in the course of the disease.

Overall survival results from the MONALESSA-3 phase III trial showed positive results for patients with advanced breast cancer, but toxicities related to the use of ribociclib still need to be addressed.

Experts are looking to use immunotherapy in different ways for patients with early-stage breast cancer.

With plenty of data from the CheckMat-227 trial to go through, one expert breaks down the vital data that will directly impact the practice.

Results from the randomized phase 3 POLO trial are in, and the quality of life data shows promise for patients with metastatic pancreatic cancer who harbor a germline BRCA gene mutation.

Advanced ovarian cancer is deadly for female patients with the disease, but results from a new study show promise for a new frontline treatment.

For patients with breast cancer with a PDL1 expression, a new treatment targeting immune cells could make a major difference.

While the findings from the most recent CARD study prove promising, it's the toxicity results that have one expert excited.

For patients with advanced prostate cancer, new findings from the CARD trial could change their daily treatment.

When patients with MCL develop resistance to chemotherapy and targeted therapies, experts believe CAR T-cell therapy can step in.

CAR T-cell therapies are a revolutionary form of treatment for patients with cancer, but it does come with its unique adverse events.

CAR T-cell therapy is changing the landscape of cancer care, but challenges for certain cancer types still remain.

Pediatric patients with ALL can expect therapies to help target their disease after they relapse, but experts are looking to combat the disease in the frontline before that.

About a third of breast cancer survivors are still living with fatigue and reduced exercise capacity after treatment ends.